{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:40:56Z","timestamp":1775547656632,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,16]]},"DOI":"10.7759\/cureus.33831","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T16:31:21Z","timestamp":1673886681000},"source":"Crossref","is-referenced-by-count":4,"title":["Paxlovid-Induced Symptomatic Bradycardia and Syncope"],"prefix":"10.7759","author":[{"given":"Venu M","family":"Ganipisetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratyusha","family":"Bollimunta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriram","family":"Maringanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO Coronavirus (COVID-19) Dashboard. (2023). Accessed. January 6, 2023: https:\/\/covid19.who.int."},{"key":"ref2","unstructured":"Covid 19 Clinical Presentation. Center for Disease Control and Prevention . (2023). Accessed. January 6, 2023: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/clinical-considerations-presentation.html."},{"key":"ref3","unstructured":"Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with High Risk for Severe COVID- 19. Information for Healthcare Providers. (2023). Accessed: January 6, 2023: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html."},{"key":"ref4","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. (2023). Accessed. January 6, 2023: https:\/\/www.covid19treatmentguidelines.nih.gov\/.."},{"key":"ref5","unstructured":"US Food and Drug Administration. Fact Sheet for Healthcare Providers. Emergency Use Authorization for Paxlovid. (2023). Accessed: January 6, 2023: https:\/\/www.fda.gov\/media\/155050\/download."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond J","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, et al.. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022, 386:1397-408. 10.1056\/NEJMoa2118542","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern","volume":"198","author":"Vangeel L","year":"2022","unstructured":"Vangeel L, Chiu W, De Jonghe S, et al.. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. Antiviral Res. 2022, 198:105252. 10.1016\/j.antiviral.2022.105252","journal-title":"Antiviral Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high risk patients","author":"Najjar-Debbiny R","year":"2022","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, et al.. Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high risk patients. Clin Infect Dis. 2022, ciac443. 10.1093\/cid\/ciac443","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb RL","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, et al.. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022, 386:305-15. 10.1056\/NEJMoa2116846","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-022-03139-y","article-title":"Efficacy and safety of molnupiravir in COVID-19 patients: a systematic review","author":"Mali KR","year":"2022","unstructured":"Mali KR, Eerike M, Raj GM, et al.. Efficacy and safety of molnupiravir in COVID-19 patients: a systematic review. Ir J Med Sci. 2022, 10.1007\/s11845-022-03139-y","journal-title":"Ir J Med Sci"},{"key":"ref11","article-title":"Half Life","author":"Hallare J","year":"2022","unstructured":"Hallare J, Gerriets V. Half Life. StatPearls (ed): StatPearls Publishing, Treasure Island, FL; 2022."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/132780-paxlovid-induced-symptomatic-bradycardia-and-syncope","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:37Z","timestamp":1707508117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/132780-paxlovid-induced-symptomatic-bradycardia-and-syncope"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.33831","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,16]]}}}